Akebia Q3 2024 net loss $20M; Vafseo launch on track for Jan 2025 with 60% dialysis patient coverage

Akebia Therapeutics, Inc.

2024-Q3 EPS reported -$0.22 revenue$113,683,000

Total revenues $37.4M in Q3 2024 vs $42.0M in Q3 2023, driven by Auryxia volume decline.
Net loss $20.0M in Q3 2024 vs $14.5M in Q3 2023, including $4.4M non-cash interest from Vifor settlement.
Cash and equivalents $34.0M as of Sep 30, 2024; company expects funding to cover operations including Vafseo launch for at least two years.
Vafseo commercial supply contracts cover over 300,000 patients (~60% of US dialysis patients); TDAPA reimbursement starts Jan 1, 2025.
U.S. market availability for Vafseo expected in January 2025; VOICE trial initiated with US Renal Care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.